Weekly Journal Scan: a penULTIMATE frontier for optimal antiplatelet therapy after drug-eluting stenting in acute coronary syndromes?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Weekly Journal Scan: a penULTIMATE frontier for optimal antiplatelet therapy after drug-eluting stenting in acute coronary syndromes?

Published:2024-06-28 Issue:34 Volume:45 Page:3108-3110
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Liuzzo Giovanna¹²^ORCID,Patrono Carlo²³^ORCID

Affiliation:

1. Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli—IRCCS , Largo A. Gemelli 8, Rome 00168 , Italy

2. Department of Cardiovascular and Pulmonary Sciences, Catholic University School of Medicine , Largo F. Vito 1, Rome 00168 , Italy

3. Center of Excellence on Ageing, CAST, ‘G. d’Annunzio’ University School of Medicine , Chieti , Italy

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/eurheartj/article-pdf/45/34/3108/59035392/ehae367.pdf

Reference12 articles.

1. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial;Ge;Lancet,2024

2. 2023 ESC guidelines for the management of acute coronary syndromes;Byrne;Eur Heart J,2023

3. Antithrombotic therapy in patients with acute coronary syndrome: similarities and differences between a European expert consensus document and the 2023 European Society of Cardiology guidelines;Landi;Eur Heart J Acute Cardiovasc Care,2024

4. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial;Vranckx;Lancet,2018

5. Efficacy and safety of ticagrelor monotherapy by clinical presentation: pre-specified analysis of the GLOBAL LEADERS trial;Vranckx;J Am Heart Assoc,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3